175 related articles for article (PubMed ID: 36710341)
1. Targeting epigenetic features in clear cell sarcomas based on patient-derived cell lines.
Karner C; Anders I; Vejzovic D; Szkandera J; Scheipl S; Deutsch AJA; Weiss L; Vierlinger K; Kolb D; Kühberger S; Heitzer E; Habisch H; Zhang F; Madl T; Reininger-Gutmann B; Liegl-Atzwanger B; Rinner B
J Transl Med; 2023 Jan; 21(1):54. PubMed ID: 36710341
[TBL] [Abstract][Full Text] [Related]
2. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
3. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.
Outani H; Tanaka T; Wakamatsu T; Imura Y; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2014 Jun; 14():455. PubMed ID: 24946937
[TBL] [Abstract][Full Text] [Related]
4. Establishment and Characterization of a Novel Human Clear-cell Sarcoma of Soft-tissue Cell Line, RSAR001, Derived from Pleural Effusion of a Patient with Pleural Dissemination.
Hakozaki M; Tamura H; Dobashi Y; Yoshida A; Kato K; Tajino T; Yamada H; Kaneuchi Y; Katahira K; Ezaki J; Waguri S; Konno S; Watanabe S
Anticancer Res; 2018 Sep; 38(9):5035-5042. PubMed ID: 30194147
[TBL] [Abstract][Full Text] [Related]
5. Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines.
Sakumoto M; Oyama R; Takahashi M; Takai Y; Kito F; Shiozawa K; Qiao Z; Endo M; Yoshida A; Kawai A; Kondo T
In Vitro Cell Dev Biol Anim; 2018 Feb; 54(2):163-176. PubMed ID: 29197033
[TBL] [Abstract][Full Text] [Related]
6. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
7. PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling.
Yao B; Gui T; Zeng X; Deng Y; Wang Z; Wang Y; Yang D; Li Q; Xu P; Hu R; Li X; Chen B; Wang J; Zen K; Li H; Davis MJ; Herold MJ; Pan HF; Jiang ZW; Huang DCS; Liu M; Ju J; Zhao Q
Genome Med; 2021 Apr; 13(1):58. PubMed ID: 33853662
[TBL] [Abstract][Full Text] [Related]
8. Methylation of C/EBPα by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.
Liu LM; Sun WZ; Fan XZ; Xu YL; Cheng MB; Zhang Y
Cancer Res; 2019 Jun; 79(11):2865-2877. PubMed ID: 31015230
[TBL] [Abstract][Full Text] [Related]
9. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations.
Tradewell ML; Yu Z; Tibshirani M; Boulanger MC; Durham HD; Richard S
Hum Mol Genet; 2012 Jan; 21(1):136-49. PubMed ID: 21965298
[TBL] [Abstract][Full Text] [Related]
10. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance.
Zhu Y; Xia T; Chen DQ; Xiong X; Shi L; Zuo Y; Xiao H; Liu L
Drug Resist Updat; 2024 Jan; 72():101016. PubMed ID: 37980859
[TBL] [Abstract][Full Text] [Related]
11. TLS and PRMT1 synergistically coactivate transcription at the survivin promoter through TLS arginine methylation.
Du K; Arai S; Kawamura T; Matsushita A; Kurokawa R
Biochem Biophys Res Commun; 2011 Jan; 404(4):991-6. PubMed ID: 21187067
[TBL] [Abstract][Full Text] [Related]
12. Roles of protein arginine methyltransferase 1 (PRMT1) in brain development and disease.
Hashimoto M; Fukamizu A; Nakagawa T; Kizuka Y
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129776. PubMed ID: 33127433
[TBL] [Abstract][Full Text] [Related]
13. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
[TBL] [Abstract][Full Text] [Related]
14. Hsa_circ_0094606 promotes malignant progression of prostate cancer by inducing M2 polarization of macrophages through PRMT1-mediated arginine methylation of ILF3.
Zhang Y; Wang K; Yang D; Liu F; Xu X; Feng Y; Wang Y; Zhu S; Gu C; Sheng J; Hu L; Xu B; Lu YJ; Feng N
Carcinogenesis; 2023 May; 44(1):15-28. PubMed ID: 36394342
[TBL] [Abstract][Full Text] [Related]
15. Protein arginine methyltransferase 1 is a therapeutic vulnerability in multiple myeloma.
Nguyen HP; Le AQ; Liu E; Cesarano A; DiMeo F; Perna F; Kapur R; Walker BA; Tran NT
Front Immunol; 2023; 14():1239614. PubMed ID: 37600810
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional down-regulation through nuclear exclusion of EWS methylated by PRMT1.
Araya N; Hiraga H; Kako K; Arao Y; Kato S; Fukamizu A
Biochem Biophys Res Commun; 2005 Apr; 329(2):653-60. PubMed ID: 15737635
[TBL] [Abstract][Full Text] [Related]
17. Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs.
Dhar S; Vemulapalli V; Patananan AN; Huang GL; Di Lorenzo A; Richard S; Comb MJ; Guo A; Clarke SG; Bedford MT
Sci Rep; 2013; 3():1311. PubMed ID: 23419748
[TBL] [Abstract][Full Text] [Related]
18. Discovery of alkyl bis(oxy)dibenzimidamide derivatives as novel protein arginine methyltransferase 1 (PRMT1) inhibitors.
Zhang WY; Lu WC; Jiang H; Lv ZB; Xie YQ; Lian FL; Liang ZJ; Jiang YX; Wang DJ; Luo C; Jin J; Ye F
Chem Biol Drug Des; 2017 Dec; 90(6):1260-1270. PubMed ID: 28636189
[TBL] [Abstract][Full Text] [Related]
19. PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells.
Chuang CY; Chang CP; Lee YJ; Lin WL; Chang WW; Wu JS; Cheng YW; Lee H; Li C
Oncol Rep; 2017 Aug; 38(2):1115-1123. PubMed ID: 28656289
[TBL] [Abstract][Full Text] [Related]
20. PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.
Song C; Chen T; He L; Ma N; Li JA; Rong YF; Fang Y; Liu M; Xie D; Lou W
Cell Oncol (Dordr); 2020 Feb; 43(1):51-62. PubMed ID: 31520395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
